Abstract

Human farnesyl pyrophosphate synthase (hFPPS) produces farnesyl pyrophosphate, an isoprenoid essential for a variety of cellular processes. The enzyme has been well established as the molecular target of the nitrogen-containing bisphosphonates (N-BPs), which are best known for their antiresorptive effects in bone but are also known for their anticancer properties. Crystal structures of hFPPS in ternary complexes with a novel bisphosphonate, YS0470, and the secondary ligands inorganic phosphate (Pi), inorganic pyrophosphate (PPi) and isopentenyl pyrophosphate (IPP) have recently been reported. Only the co-binding of the bisphosphonate with either PPi or IPP resulted in the full closure of the C-terminal tail of the enzyme, a conformational change that is required for catalysis and that is also responsible for the potent in vivo efficacy of N-BPs. In the present communication, a co-crystal structure of hFPPS in complex with YS0470 and two molecules of Pi is reported. The unusually close proximity between these ligands, which was confirmed by anomalous diffraction data, suggests that they interact with one another, with their anionic charges neutralized in their bound state. The structure also showed the tail of the enzyme to be fully disordered, indicating that simultaneous binding of two Pi molecules with a bisphosphonate cannot induce the tail-closing conformational change in hFPPS. Examination of homologous FPPSs suggested that this ligand-dependent tail closure is only conserved in the mammalian proteins. The prevalence of Pi-bound hFPPS structures in the PDB raises a question regarding the in vivo relevance of Pi binding to the function of the enzyme.

Highlights

  • Human farnesyl pyrophosphate synthase occupies the first branching point in the mevalonate pathway and carries out the elongation of dimethylallyl pyrophosphate (DMAPP) to geranyl pyrophosphate (GPP) and to farnesyl pyrophosphate (FPP) by successively condensing two molecules of isopentenyl pyrophosphate (IPP)

  • The mechanism by which nitrogen-containing bisphosphonates (N-BPs) inhibit Human farnesyl pyrophosphate synthase (hFPPS) has been well characterized by X-ray crystallographic studies (Kavanagh et al, 2006; Rondeau et al, 2006)

  • By determining and analyzing crystal structures of hFPPS in ternary complexes with a novel bisphosphonate inhibitor, YS0470, and the secondary ligands inorganic phosphate (Pi), inorganic pyrophosphate (PPi) and IPP, we recently identified the key residues and interactions responsible for the tail closure of the enzyme (Park et al, 2012)

Read more

Summary

Introduction

Human farnesyl pyrophosphate synthase (hFPPS) occupies the first branching point in the mevalonate pathway and carries out the elongation of dimethylallyl pyrophosphate (DMAPP) to geranyl pyrophosphate (GPP) and to farnesyl pyrophosphate (FPP) by successively condensing two molecules of isopentenyl pyrophosphate (IPP). Nitrogen-containing bisphosphonates (N-BPs), such as zoledronate and risedronate, comprise the only class of clinically approved drugs targeting hFPPS. These drugs have been widely used against bone-resorption disorders, but are gaining a great deal of interest for their anticancer properties (Koul et al, 2012). The mechanism by which N-BPs inhibit hFPPS has been well characterized by X-ray crystallographic studies (Kavanagh et al, 2006; Rondeau et al, 2006). They bind to the DMAPP/GPP subpocket of the active site, mimicking and competing with these substrates. While hFPPS cycles doi:10.1107/S2053230X14002106 299 structural communications

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call